Welcome to Valicare!
-
Give us a call: +49 69 153 293 701
Learn more -
ATMP Basics Seminar on 28. and 29.04.2021: inform and register now!
Learn more
Events
-
11 May 202114 May 2021Vienna / Austria PBP World Meeting 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
-
28 May 2021Stuttgart / Germany German Biotech Days (DBT) Germany's largest biotech event, the German Biotechnology Days 2021 (DBT), the forum for all stakeholders in Germany’s biotech scene to exchange views and experiences, will take place on 20th and 21th September 2021 in Stuttgart.
News from around the world
Our international press review shows a selection of news and latest articles on Advanced Therapy Medicinal Products (ATMP), Chimeric Antigen Receptor (CAR) T-Cell Therapy, Tumor Infiltrating Lymphocytes (TIL) and tissue engineerd products (TEP).
Ein Hoffnungsschimmer: Neue Waffe im Kampf gegen Lebererkrankungen
01.05.2021 | ZephyrnetNiigata, Japan - Forscher der Niigata University, der University of Tokyo, der Osaka University und der Tokyo Medical University, Japan ...
A Look Back at the FDA News from April 2021
30.04.2021 | Targeted OncologyDuring April, the FDA granted approvals to 6 therapies across KRAS wild types, triple-negative breast cancer, gastric cancer, endometrial ...
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
30.04.2021 | Le Lezard (EN)
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade
30.04.2021 | FrontiersDespite major advances in immunotherapy, hepatocellular carcinoma (HCC) remains a challenging target. Natural Killer (NK) cells are crucial ...
How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
29.04.2021 | Science DirectHighlights The tumor microenvironment forms a metabolic barrier against cytotoxic CD8+ T cells, thus hampering current immunotherapeutic ...
Pharmastandort Deutschland nach Corona-Pandemie: Mehr Mut, mehr bewegen
29.04.2021 | Pharma Fakten
Smart cell therapies for solid cancers ready to move toward clinical trials
29.04.2021 | Medical XpressImmunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of ...
Revolutioniert LEOPARD die Diagnostik?
29.04.2021 | Frankfurt-Live
Researchers Present New Insights in the Fight Against COVID-19
28.04.2021 | Laboratory EquipmentScientists from around the world are gathering to share the latest research at the forefront of biology during the Experimental Biology (EB ...
FDA Grants Orphan Drug Designation to Novel TIL Therapy for Advanced-Stage Melanoma
27.04.2021 | Targeted OncologyThe FDA has granted orphan drug designation to ITIL-168 for the treatment of stage IIB to IV melanoma, an investigational, autologous cell ...
EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001
27.04.2021 | PharmaTimesVertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy CTX001 has been granted a Priority Medicines (PRIME) designation from the ...
Clinical Catch-Up: April 19-23
26.04.2021 | Bio SpacePublished: Apr 26, 2021 By Mark Terry It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 ...
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
24.04.2021 | Science DirectHighlight • The emergence of CAR-T cell therapy with its exciting results attained in patients with relapsed and refractory hematological ...
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
23.04.2021 | FrontiersMacrophages are crucial innate immune cells that maintain tissue homeostasis and defend against pathogens; however, their infiltration into ...
Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
22.04.2021 | FrontiersNeuroblastoma is the most common extracranial childhood solid tumor. The majority of high-risk neuroblastoma is resistant/refractory to the ...
Valicare – competent, reliable & efficient
You have little time and still want to know what services Valicare GmbH offers?